A previous study demonstrated that the molecular biology features of cHCC are more similar to those of hepatocellular carcinoma (HCC) than of iCCA, therefore, multitargeted inhibitors, including lenvatinib, regorafenib, and cabozantinib, may have potential for benefit in cHCC due to frequent alterations in RTK/Ras/PI3‐kinase pathways (22). Here, PRRT2 is linked to hepatocellular carcinoma.